From GlobeNewswire: 2025-04-25 13:17:00

At the AACR 2025 meeting, Pyxis Oncology presented data on their ADC therapeutic, MICVO, showing gene signatures linked to enhanced efficacy in PDX models. MICVO’s mechanism involves tumor killing and immunogenic cell death, supported by preclinical studies. Combining a mouse analog of MICVO with anti-PD-1 therapy in a syngeneic model led to improved tumor clearance and long-lasting immunological memory. These findings highlight the potential of MICVO as a monotherapy and in combination therapy for various solid tumors, as detailed in posters presented at the conference. MICVO is currently being evaluated in Phase 1 studies for advanced solid tumors and in combination with KEYTRUDA®.



Read more at GlobeNewswire: Pyxis Oncology Presents Promising Preclinical Results